
price close busi januari
domin global leader next
gener sequenc instrument
biomed devic servic
start year reiter buy trim pt
offer littl increment news call given pre-announc
earlier month expect share open modestli part due novaseq
number unit miss compani fy guid
revenue guid come street total cadenc rev expect
back-end load foreseen rev vs part
due cautiou outlook direct-to-consum test said
revenu guid appear conserv us demand remain
robust global buy thesi intact though trim pt
assign slightli lower multipl stock still impli upsid
overview revenu y/ line pre-announc
beat driven y/i growth sequenc consum
novaseq instrument grow y/i well
servic revenu y/i miss
estim adj ep came adj gm
y/i miss adj om miss
posit instrument beat us new record
driven novaseq quarter second-highest nextseq shipment
revenu compani histori driven oncolog nipt guid
msd increas instrument rev well estim
demonstr confid novaseq upgrad cycl hiseq user
convert play sever year sequenc consum
rev grew solid y/i guid y/i seq
consum growth
neg guid rev q/q vs level
street miss us gm om guid gm slightli
y/i due mix shift pop seq larg scale come lower unit econom
novaseq deliv record novaseq consum pull-through record
novaseq placement novaseq place vs still
hiseq custom order singl novaseq yet
dtc mysteri comment expect start slow
array despit growth genotyp volum expect lsd
growth acceler growth ou greater interest
health trait peopl genotyp world popul
think wrong investor worri market hit wall best guess
may migrat array exom ancestri
may take pedal metal kit discount
guide/model reiter revenue guid growth y/i adj
ep line prior top line
rais rev adj ep
rais rev
street adj ep street
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
big pictur updat mean far result guid
earlier month estim less human
sequenc less speci sequenc
variant discov genom deciph yet agre
remain begin shift precis medicin research
applic clinic said also think remain begin term
research applic call cite new studi tri understand
link microbiom colon cancer think one data point among
mani indic much much learn molecular biolog diseas
incid diseas treatment
dtc mysteri nearli direct-to-consum test order alon
use array technolog perform
year ago bit concern would tough comp
clearli mark banner year dtc test said take
cautiou view dtc busi base convers
custom would disclos detail suspicion
and/or ancestri could migrat array exom plu either
provid may take pedal metal kit discount think wrong
investor worri dtc test hit wall expect dtc array
busi reacceler later driven grow interest consum health
applic instanc helix new app mayo clinic among other
like continu contribut growth fairli recent fda-author
guid expect revenu declin sequenti specifi
much said compani gave us piec sequenc instrument
revenu declin note greater prior two year
appear bit conserv us sequenc consum flat slightli
q/q sequenc servic flat microarray grow q/q
mid- high-singl digit base compon model revenu
y/i note comp robust y/i quarter
model revenu approxim full-year total
consist compani guid greater revenu
array servic total services/oth rev ex-freight y/i
light estim microarray consum y/i beat
estim microarray instrument revenu beat came well
strong level microarray servic rev
declin y/i line manag earli januari commentari
expect microarray revenu grow q/q mid- high-single-digit rang
full year expect array revenu grow low-single-digit rang reflect
cautiou view direct-to-consum opportun base convers
compani larg custom
plan begin ship new novaseq flow cell prime februari
prime gear toward smaller core lab prime provid fastest
run time lowest run cost longest read novaseq referenc
prime flow cell ideal upgrad user hiseq indic
hudsonalpha institut earli access custom prime flow cell use
prime flow cell immun profil
exom patient talk larg health systems/idn
exom sequenc patient clinic set indic
partnership geising spur convers larg system
integr deliveri network believ greater adopt systemat would
add major upsid sequenc consum growth think take
time play
buy unchang target price januari
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
buy unchang target price januari
biomed devic servic
buy unchang target price januari
biomed devic servic
buy unchang target price januari
biomed devic servic
buy unchang target price januari
biomed devic servic
